Advice

In the absence of a submission from the holder of the marketing authorisation.

fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the prevention of venous thromboembolic events (VTE) in medical patients who are judged to be at high risk of VTE and who are immobilised due to acute illness, such as cardiac insufficiency and/or acute respiratory disorders, and/or acute infections or inflammatory disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.

Download detailed advice29KB (PDF)

Download

Medicine details

Medicine name:
fondaparinux (Arixtra)
SMC ID:
261/06
Indication:
Prevention of venous thromboembolic events
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Cardiovascular system
Submission type
Non submission
Status
Not recommended
Date advice published:
08 May 2006